Fig 1: Co-culture of enteric glial cells (EGC) with Caco2 cells stabilizes epithelial barrier function. (A). Measurements of transepithelial electric resistance (TER) showed a significant increase beginning at 8 h after incubation with the supernatant of EGC and raised to 3.01 ± 0.1-fold of baseline (equates to 2.24-fold of controls) while incubation with glial cell line-derived neurotrophic factor (GDNF) at 100 ng/mL increased TER significantly to 2.99 ± 0.07 of baseline (2.23-fold of controls) after 24 h. Similar results were obtained when GDNF was applied at 80 pg/mL when TER increased to 2.52 ± 0.09 -fold of baseline (1.88-fold of controls); (n = 6, * = significant different vs. control after 8 h for all other conditions; p < 0.05, two-way ANOVA). Control = Caco2 monolayer without treatment. (B). Western Blots of Caco2 cells and EGC cells (wilde type (WT) and GDNF-knockdown) confirmed that all these cell lines express GDNF receptors and RET (n = 3). Quantification of the blots is shown in Supplementary Figure S1 (C). Schematic picture of the co-culture model of Caco2 cells and enteric glia cells. (D). Permeability coefficients (PE) of 4-kDa FITC dextran flux across Caco2 monolayers were significantly reduced 24 h after co-culture with EGC (p < 0.05, n = 16, student’s t-test). Control = Caco2 monolayer without treatment. (E). Immunostaining of the transwell filters showed an augmented and more linear staining pattern of desmosomal protein Desmoglein2 (Dsg2), adherens junction protein E-Cadherin and tight junction protein Claudin1 24 h after co-culture of confluent Caco2 cells with EGC compared to untreated controls (representatives are shown for n = 10, scale = 20 µm). Control = Caco2 monolayer without treatment.
Fig 2: Enteric glial cells (EGC) express and secrete Glial cell line-derived neurotrophic factor (GDNF) at physiologically-relevant doses in vivo and in vitro. (A). Immunostaining of glial fibrillary acidic protein (GFAP) in the intestine from GFAPcre x Ai14floxed showed a co-localization of the inducible fluorescence protein tdTomato (red) and GFAP (green) at the plexus myentericus. (n = 8, scale 50µm). (B). qPCR of tdTomato positive cells that were sorted by Fluorescence-activated cell sorting (FACS) revealed that the cells express glial markers Sox10 and GFAP ex vivo and in primary cell culture (PC) (n = 5). (C). qPCR of that cells confirmed that tdTomato positive cells express GDNF ex vivo and in primary cell culture (n = 7). (D). GDNF ELISAs were performed of human (n = 5) and murine ileum lysates (n = 4) showing levels of GDNF at 56.0 ± 4.3 pg/mL and 42.6 ± 7.4 pg/mL. In supernatants from EGCs (CRL2690) (n = 4) GDNF levels of 88.7 ± 5.5 pg/mL and of primary EGCs GDNF levels of 241.7 ± 44.4 pg/mL were detected (n = 7; * = p < 0.05). (E). Lysates of primary EGCs as well as CRL2690 cells are positive for GDNF in Western Blots (n = 8). Quantification of the GDNF blots is shown in Supplementary Figure S1.
Fig 3: Effects of enteric glial cells (EGC) on organoids after the inflammation-induced breakdown of the intestinal barrier are dependent on RET-mediated pathways. (A): Representative images of organoids 1 h after incubation with 4 kDa FITC-Dextran are shown. Compared to controls (a) Tumor necrosis factor a (TNFa) increased the fluorescence inside the organoids (b), while simultaneous application of recombinant glial cell line-derived neurotrophic factor (GDNF) (c) or EGC supernatants attenuated (e) this inflammation-induced breakdown of the intestinal epithelial barrier, while RET inhibitor Blue667 blocked the effects of GDNF and EGC on organoid permeability (d,f). (representative figures are shown for n = 7, scale 120 µm); control = organoids without treatment. (B): Permeability in organoids was quantified by the quotient of the fluorescence in the organoid lumen and outside of the organoid. These measurements revealed an inflammation-induced increase to 1.94 ± 0.09-fold of controls. Incubation with GDNF or EGC supernatants reduced the effects of TNFa and the permeability quotient was reduced to 1.11 ± 0.08-fold of controls. This protective effect of EGC supernatants was blunted by concurrent application of Blue667, where the permeability quotient increased again to 2.04 ± 0.07-fold of controls (n = 7; * = p < 0.05; One-way ANOVA); control = organoids without treatment. (C): Representative immunostaining for junctional proteins Desmoglein2 (Dsg2), E-Cadherin, Claudin1 and 5 are shown. TNFa reduced the staining pattern of the tight junction proteins Claudin1 and 5 as well as the staining of Dsg2 at the cell borders (b,h,n,t). This effect was attenuated when organoid cells were cultivated with recombinant GDNF and EGC supernatants (c,i,o,u and e,k,q,w). The beneficial effects of EGC supernatants were blocked by RET Inhibitor Blue667 (d,j,p,v and f,l,r,x) (representatives are shown for n = 6, Scale bar = 80 µm); control = organoids without treatment (a,g,m,s).
Fig 4: Effects of enteric glial cells (EGC) on epithelial barrier function are RET-dependent. (A). Representative Western blots of Caco2 cells are shown. Glial cell line-derived neurotrophic factor (GDNF) increased the ratio of phosphorylated RETY1062 to 131 ± 9%- of controls, while application of Blue667 reduced basal phosphorylation of RET and blocked GDNF-induced RET phosphorylation to 67.5 ± 9% of controls; (n = 8). (B). Quantification of the western blots are shown which demonstrated that GDNF increased RET phosphorylation to 131.1 ± 9% of controls whereas Blue667 reduced RET phosphorylation; (n = 8, Kruskal Wallis Test); Control = Caco2 monolayer without treatment. (C,D). Transepithelial electric resistance (TER) measurements of Caco2 monolayers are shown. The inhibition of the RET by Blue667 blocked the effect of GDNF and of EGC supernatant on intestinal epithelial barrier maturation; (n = 8 for each set of experiments; * p < 0.05; 2-way ANOVA); Control = Caco2 monolayer without treatment.
Fig 5: Tumor necrosis factor a (TNFa) increased the expression and secretion of glial cell line-derived neurotrophic factor (GDNF) in enteric glial cells (EGC). (A). Representative Western blot of EGC cell lysates showing that TNFa and lipopolysaccharide (LPS) but not lipoteichoic acid (LTA) led to increased expression of GDNF, membranes were reprobed for ß-actin to ensure equal protein loading; (n = 9). (B). Quantification of all Western blots showed a significantly increased expression of GDNF by TNFa and LPS but not by LTA; (n = 9; * = p < 0.05, Kruskal Wallis Test); Control = Caco2 monolayer without treatment. (C). Representative Western blot of EGC cell culture supernatants is shown which demonstrates increased release of GDNF by TNFa and LTA but not LPS; (n = 9). (D). Quantification of all Western blots showed a significantly increased release of GDNF by TNFa and LTA but not by LPS (n = 9; * = p < 0.05, Kruskal Wallis Test); Control = Caco2 supernatant without treatment. (E). MTT assays served to test for cell viability. Except for incubation with staurosporine EGC cell viability was not changed for the different experimental conditions (n = 10; * = p < 0.05 control, TNFa, LPS, LTA vs. Strauosporine; Kruskal Wallis Test); Control = Caco2 monolayer without treatment.
Supplier Page from Abnova Corporation for Gdnf (Mouse) ELISA Kit